PDCD1 and neoplasm: VEGFR inhibitors might potentially improve immunotherapeutic activity of PD-1/PD-L1 antibodies by enhancing tumor infiltration of immune cells and reducing immunosuppressive effects of myeloid-derived suppressor cells [122].